ADMA Biologics Faces Valuation Shift Amid Declining Profit and Operational Challenges

ADMA Biologics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced an adjustment in its evaluation. The revision in its score reflects a shift in valuation metrics, indicating a transition from a previously assessed level to a more elevated classification. Key financial indicators reveal a P/E ratio of 15, alongside a Price to Book Value of 4.62. The company maintains a strong position with a return on equity (ROE) of 31.34% and a return on capital employed (ROCE) of 41.35%. However, the latest financial results for the quarter ending March 2026 show a decline in net profit, which stands at USD 94.71 million, reflecting a year-over-year decrease. Additionally, the inventory turnover ratio and debtors turnover ratio have reached their lowest points, suggesting potential operational inefficiencies. Despite being net-debt free and achieving a notable annual growth rate of 64.60% in net sales, ADMA Biologics has underperformed relative to the broader market, with a significant negative return over the past year. The company’s high institutional holdings may provide a buffer, as these investors typically possess greater analytical resources. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.